Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

Main
News

News

Admin
Feb 21 2025

[Press Release]

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

https://www.alphatau.com/single-post/alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-pilot-trial-of-alpha-dart-to-thirty-pa

Previous: Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day Feb 21 2025

Next: UltraSight to Expand Access to Echocardiographic Monitoring for Obstructive Hypertrophic Cardiomyopathy Patients Feb 21 2025

List